Your browser doesn't support javascript.
loading
Advancements of prodrug technologies for enhanced drug selectivity in pharmacotherapies.
Li, Helin; Zhang, Wenjing; Meng, Qiu; Shuai, Qi.
Afiliação
  • Li H; Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, Zhejiang, 310014, China.
  • Zhang W; Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, Zhejiang, 310014, China.
  • Meng Q; College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, Zhejiang, 310014, China. mengq@zjut.edu.cn.
  • Shuai Q; Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, Zhejiang, 310014, China. qshuai@zjut.edu.cn.
Invest New Drugs ; 2024 Aug 13.
Article em En | MEDLINE | ID: mdl-39136898
ABSTRACT
The therapeutic effects of many pharmacotherapies have been explored, but disadvantages such as low drug specificity, drug resistance and side effects makes their effective delivery to target sites a great challenge. Consequently, a distinctive prodrug-based technology have emerged as an effective treatments because of their distinctive advantages, such as high drug loading capacity, precise targeting, reduced side effects and spatial and temporal controllability. In particular, the use of gamma/X-ray-mediated strategies in radiotherapy is a new strategy that could enable the precise drug release from implanted devices. This review presents readers with the current state of prodrug therapy and reports the design protocols of rational and effective prodrugs for clinical use.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Invest New Drugs Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Invest New Drugs Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China